ImmunityBio, Inc DEFA14A, filed Apr 29, 2022
ImmunityBio, Inc. (IBRX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement |
| ☒ | Definitive Additional Materials |
| ☐ | Soliciting Material Under §240.14a-12 |
ImmunityBio, Inc.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if Other than Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ | No fee required. |
| ☐ | Fee paid previously with preliminary materials. |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
P.O. BOX 8016, CARY, NC 27512-9903 |
ImmunityBio, Inc. Important Notice Regarding the Availability of Proxy Materials
Annual Meeting of Stockholders to be held on June 14, 2022
For Stockholders of Record as of April 18, 2022
This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.
To view the proxy materials and obtain directions to attend the meeting live via webcast, go to: www.proxydocs.com/IBRX.
To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.
Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. |
|
|
For a convenient way to view proxy materials and VOTE go to www.proxydocs.com/IBRX. |
| ||
|
Have the 12
digit control number located in the shaded box above available
| ||||
| If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 3, 2022. | ||||
To order paper materials, use one of the following methods:
|
INTERNET www.investorelections.com/IBRX |
TELEPHONE |
* E-MAIL | ||||||
|
When requesting via the Internet or telephone, you will need the 12 digit control number located in the shaded box above. |
* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. | |||||||
| ImmunityBio, Inc. | ||
| Meeting Type: | Annual Meeting of Stockholders | |
| Date: Tuesday, June 14, 2022 | ||
| Time: 9:30 AM, Pacific Time | ||
| Place: Annual Meeting to be held live via the Internet. | ||
| Please visit www.proxydocs.com/IBRX for more details. | ||
|
You must register to attend the Annual Meeting online and/or participate at www.proxydocs.com/IBRX. | ||
|
SEE REVERSE FOR FULL AGENDA
| ||
ImmunityBio, Inc.
Annual Meeting of Stockholders
THE BOARD OF DIRECTORS RECOMMENDS A VOTE:
| FOR ON PROPOSALS 1, 2 AND 3 |
| PROPOSAL |
| 1. | To elect nine directors from the nominees named in the proxy statement to serve until our 2023 annual meeting of stockholders and until their respective successors are duly elected and qualified or until their earlier resignation or removal. |
| 1.01 Patrick Soon-Shiong, M.D. |
| 1.02 Richard Adcock |
| 1.03 Barry J. Simon, M.D. |
| 1.04 Michael D. Blaszyk |
| 1.05 John Owen Brennan |
| 1.06 Wesley Clark |
| 1.07 Cheryl L. Cohen |
| 1.08 Linda Maxwell, M.D. |
| 1.09 Christobel Selecky |
| 2. | To approve an amendment to the ImmunityBio, Inc. 2015 Equity Incentive Plan to increase the number of shares of the company’s common stock authorized for issuance under the plan by 19,900,000 shares. |
| 3. | To ratify the selection of Ernst & Young LLP as ImmunityBio’s independent registered public accounting firm for the fiscal year ending December 31, 2022. |
| 4. | To transact other business that may properly come before the Annual Meeting. |